GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40122)

  • GC80875 structure
    GC80875PROTAC survivin degrader-1
    CAS: 3079079-69-6
    Purity: >98.00%

    PROTAC survivin degrader-1 is an orally active, CNS-penetrant survivin -targeting PROTAC.

  • GC80876 structure
    GC80876G9D-4 TFA
    Purity: >99.00%

    G9D-4 TFA is a G9a PROTAC degrader.

  • GC80877 structure
    GC80877LD-110 triTFA
    Purity: >99.50%

    LD-110 triTFA is a highly efficient and effective LSD1 PROTAC degrader ( DC 50 = 0.44 μM).

  • GC80878 structure
    GC80878RIPK2 ligand 3
    CAS: 2027561-86-8
    Purity: >99.00%

    RIPK2 ligand 3 is a RIPK2 ligand and can be used for the synthesis of PROTACs, such as PROTAC RIPK degrader-2 [1] .

  • GC80879 structure
    GC80879JWZ-8-103 hydrochloride
    Purity: >99.50%

    JWZ-8-103 hydrochloride is an orally active analog of PRLX-93936 and a molecular glue targeting TRIM21.

  • GC80880 structure
    GC80880dCASP1-55
    Purity: >98.00%

    dCASP1-55 is a cereblon-dependent caspase-1 ( CASP1 ) PROTAC degrader.

  • GC80881 structure
    GC80881PROTAC DAPK1 Degrader-1
    CAS: 3063030-38-3
    Purity: >96.50%

    PROTAC DAPK1 Degrader-1 is a death-associated protein kinase 1 (DAPK1) degrader with a DC 50 of 119.6 nM.

  • GC80882 structure
    GC80882ZLY025
    CAS: 3070379-34-6
    Purity: >99.00%

    ZLY025 is a potent and orally active CCNK molecular glue degrader with an DC 50 of 42.7 nM.

  • GC80883 structure
    GC80883Thalidomide-O-amide-C5-NH2 hydrochloride
    CAS: 2716130-28-6
    Purity: >95.50%

    Thalidomide-O-amide-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology [1] [2] .

  • GC80884 structure
    GC80884CXJ2080
    Purity: >98.00%

    CXJ2080 is a selective PROTAC-based CDK7 degrader with a DC 50 of 0.88 nM.

  • GC80885 structure
    GC80885PROTAC CDK6 Degrader 1
    Purity: >98.50%

    PROTAC CDK6 Degrader 1 (compound 48a) is a potent and selective PROTAC CDK6 degrader with a DC 50 of 0.037 μM.

  • GC80886 structure
    GC80886PROTAC CDK2/4/6 Degrader-2
    CAS: 2541626-49-5
    Purity: >97.00%

    PROTAC CDK2/4/6 Degrader-2 is a CDK2/4/6 PROTAC degrader.

  • GC80887 structure
    GC80887MA203
    Purity: >98.00%

    MA203 is a selective CHK1 PROTAC degrader.

  • GC80888 structure
    GC80888PROTAC PLK1 Degrader-2
    Purity: >99.00%

    PROTAC PLK1 Degrader-2 is a peptide-based N-end rule PLK1 mini-PROTAC.

  • GC80889 structure
    GC80889PROTAC HDAC4 Degrader-2
    CAS: 3035189-46-6
    Purity: >98.00%

    PROTAC HDAC4 Degrader-2 is a class IIa selective negative control for HDAC4 PROTAC degraders, with an IC 50 of 0.15 μM against HDAC4 and a cellular IC 50 of 0.18 μM.

  • GC80890 structure
    GC80890NEK7 degrader-3
    CAS: 3119435-52-5
    Purity: >98.00%

    NEK7 degrader-3 is an orally active and brain-penetrant NEK7 molecular glue degrader with a DC 50 of 33.1 nM.

  • GC80891 structure
    GC80891NK7-902 diTFA
    Purity: >99.50%

    NK7-902 diTFA is a selective and orally active CRBN-dependent NEK7 molecular glue degrader with K d values of 1.5 and 2.6 μM for hNEK7 and mNEK7.

  • GC80892 structure
    GC80892SR-5037
    CAS: 2387704-74-5
    Purity: >99.50%

    SR-5037 is an orally active CDK12 ( IC 50 = 31 nM)/ CDK13 inhibitor and CycK ( DC 50 = 30 nM; D max > 98%) molecular glue degrader.

  • GC80893 structure
    GC80893PROTAC CDK2/4 Degrader-1
    Purity: >98.00%

    PROTAC CDK2/4 Degrader-1 is a PROTAC degrader of cyclin-dependent kinase 2 ( CDK2 ) and cyclin-dependent kinase 4 ( CDK4 ).

  • GC80894 structure
    GC80894(S)-JWZ-5-13
    Purity: >99.50%

    (S)-JWZ-5-13 (compound 17-Neg), a PROTAC CDK7 degrader, is a negative control compound of JWZ-5-13.

  • GC80895 structure
    GC80895PROTAC USP39 Degrader-1
    Purity: >98.00%

    PROTAC USP39 Degrader-1 is a USP39 PROTAC degrader with K d values of 136 nM and 232 nM, and a DC 50 value of 1.06 nM (24 h).

  • GC80896 structure
    GC80896PROTAC D16-M1P2
    Purity: >98.00%

    PROTAC D16-M1P2 is an orally active CRBN -mediated selective PKMYT1 PROTAC degrader, with a DC 50 of 0.7 nM in CCNE1-amplified HCC1569 breast cancer cells.

  • GC80897 structure
    GC80897Desamino lenalidomide-C2-COOH
    CAS: 2703770-71-0
    Purity: >98.00%

    Desamino lenalidomide-C2-COOH is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.

  • GC80898 structure
    GC80898Thalidomide-O-C2-alkyne
    CAS: 2357110-34-8
    Purity: >99.50%

    Thalidomide-O-C2-alkyne is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.